J. Souness

Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease

F. Brito, J. Souness, P. Warne, 1997 .

Phosphodiesterase type IV inhibitors.

M. N. Palfreyman, J. Souness, J. Souness, 1996, Progress in medicinal chemistry.

Potential of p38 inhibitors in the treatment of rheumatoid arthritis.

M L Foster, M. Foster, F Halley, 2000, Drug news & perspectives.

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.

I. McLay, S. Phipps, M. Belvisi, 2001, Bioorganic & medicinal chemistry.

A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.

B. O'connor, C. Page, D. Spina, 2000, Pulmonary pharmacology & therapeutics.

Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.

J. Mason, S. Djurić, B. Hanney, 1998, Journal of medicinal chemistry.

Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis.

M. Foster, J. Souness, 1998, IDrugs : the investigational drugs journal.